A doctor injects a patient with Allergan’s Botox. Photographer: Patrick T. Fallon/Bloomberg

Botox maker Allergan, which is fending off an acquisition by Valeant Pharmaceuticals, said today that it had been approached by another party regardi(...)

Botox producer Allergan  is resisting Valeant’s hostile offer. Photograph: Shannon Stapleton/Reuters

Valeant Pharmaceuticals said in a letter yesterday to Allergan’s board of directors that it was prepared to raise its offer to at least $200 per share(...)

The head offices of Valeant Pharmaceuticals  in Laval, Quebec. The Canadian-based company said Allergan’s refusal to enter talks left it with no option but to go hostile in the battle for control of its US rival. Photograph: Christinne Muschi/Reuters

Valeant Pharmaceuticals is preparing to take its bid for Allergan direct to shareholders after its latest $53 billion offer was rejected by the mak(...)

Workers leaving the Bausch & Lomb plant in Waterford yesterday. Photograph: Mary Browne

“Valeant’s model of cutting and slashing really doesn’t work for more than a very short period of time.”The words are those of Allergan chief executiv(...)

Dr Keith Marcus injects Botox between a patient’s eyes. Valeant Pharmaceuticals International has offered to buy Allergan, the maker of the Botox wrinkle treatment, in a cash-and-stock deal valued at $45.7 billion. Photographer: Patrick  Fallon/Bloomberg

US drugmaker Allergan today rejected Valeant Pharmaceuticals International’s $47 billion takeover offer, saying its proposed cost cuts were too steep.(...)

Pfizer’s plan to move its domicile to Britain by acquiring AstraZeneca would lower its taxes. Photograph: getty images

Rumours about a massive healthcare deal were circulating in industry circles, months before Pfizer disclosed its $100 billion pursuit of Britain’s Ast(...)